In reaction to strong earnings/guidance: STX +13.7%, NEPT +13.7%, AA +3.7%, ( Cube Hydro Carolinas reaches agreement to acquire hydroelectric plants from Alcoa Power Generating)
M&A news:
- RRD +5.7% (reports of RR Donnelley & Sons potential merger with Xerox's Copy unit)
- XRX +2.3%
Select metals/mining stocks trading higher: CLF +6.7%, MT +4.2%, FCX +3.9%, VALE +2.3%, SBGL +1.6%, RIO+1.6%, GFI +1.2%, BHP +1%
Select oil/gas related names showing strength: SDRL +4.9%, TOT +2.8%, MRO +2.7%, SWN +2.7%, RDS.A +1.7%,BP +1.5%
Other news:
- SAGE +41.9% (announces positive top-line results from its Phase 2 clinical trial of SAGE-547)
- JRJR +13.6% ( compliance plan was accepted by NYSE MKT relating to failure to timely file its Quarterly Report on Form 10-Q)
- BAA +12.8% (reports Q2 operating results)
- BDSI +11.2% ( secured preferred formulary status for BUNAVAIL on a 'significant' managed care plan )
- CEL +8.4% (Company commenced legal actions against Golan Telecom, including a request for an interim injunction against the consummation of the Golan Telecom - Hot Mobile agreement)
- MGT +7.4% (following late pullback -- released prelim proxy statement)
- CASC +5.7% (Growth Equity Opportunities Fund discloses 8.3% active stake)
- SHPG +5.2% (receives FDA approval for Xiidrag)
- BLFS +5.1% (following Monday's 50%+ move higher)
- WDC +4.1% (on STX guidance)
- RLYP +3.7% (discloses new patient starts, outpatient prescriptions and units sold to hospitals/other institutions for June)
- CLDX +3.1% (initiates Phase 1/2 clinical trial of new product candidate CDX-014 in advanced renal cell carcinoma)
- REN +3% (following Monday's 50%+ move higher; also John C. Goff increases active stake to 9.9%)
- STM +2.5% (in sympathy with STX)
- GSS +2% ( Pre-commercial production has commenced at its Wassa Underground Mine in Ghana, as scheduled)
- NTIP +1.4% ( discloses settlement of patent litigation with Alcatel-Lucent Entities and ALE)
- UAL +1.4% (reported June 2016 operational results; expects Q2 passenger unit revenue to decline 6.50% to 6.75% YoY, citing several headwinds )
- CHK +4.3% (upgraded to Neutral from Underweight at Piper Jaffray)
- GFI +1.2% (upgraded to Neutral from Underweight at JP Morgan)
- ORCL +1.0% (upgraded to Outperform from Market Perform at BMO Capital Markets)
In reaction to disappointing earnings/guidance:
- IMPV -5.5%, ( lowers Q2 guidance citing impacts by extended sales cycles across most geographies and verticals predominantly relating to larger deals)
- FAST -1.8%
- CYTR -65.3% ( announces results of an analysis of its Phase 3 clinical trial of aldoxorubicin compared to investigator's choice therapy in patients with relapsed or refractory soft tissue sarcomas; study did not show a significant difference between aldoxorubicin and investigator's choice therapy for PFS)
- CKEC -2.5% (AMC Entertainment (AMC) says remains committed to moving forward with plan to acquire Carmike despite announcing it would acquire Odeon & UCI Cinemas Group)
- ALR -2.4% (Alere to initiate voluntary withdrawal of the Alere INRatio and INRatio 2 PT/INR monitoring system)
- REG -2.3% (prices 4.35 mln common stock offering; will be no impact to Core Funds from Operations as a result of these one-time charges; however, the combined one-time charges will reduce net income attributable to common stockholders per share and NAREIT FFO/share by ~$0.58 in 3Q16)
- CHRS -1.3% (after closing near highs -- up 25% on the day)
- PANW -1.1% (in sympathy with IMPV guidance)
- TSLA -0.8% (WSJ reported potential SEC investigation)
- DRD -5.2% (downgraded to Underweight from Neutral at JP Morgan)
- CBB -1.7% (downgraded to Hold from Buy at Gabelli & Co)
- FIT -1.3% (initiated with a Market Perform at Wells Fargo)
- AWI -1% (downgraded to Sell from Neutral at Goldman)
- VOD -0.9% (downgraded to Neutral from Buy at Citigroup)
Early premarket gappers
Gapping up: NEPT +13.7%, JRJR +13.6%, BAA +12.8%, STX +12.5%, BDSI +11.2%, CEL +8%, MGT +7.4%, LYG +5.9%, SDRL +5.9%, CASC +5.7%, DB +5.7%, SHPG +5.3%, BCS +5.1%, CHK +4.8%, RRD +4.4%, MT +4.4%, SAN +4.3%, RBS +4%, CLF +4%, AA +3.7%, WDC +3.6%, ING +3.2%, CLDX +3.1%, MRO +3.1%, RLYP +3%, FCX +3%, STM +2.5%, VALE +2.5%, XRX +2.3%, SBGL +2.3%, RIO +2.2%, RDS.A +1.9%, BHP +1.6%, NTIP +1.4%, UAL +1.4%, HSBC +1.4%, BP +1.2%, GFI +1.2%, BBL +1.2%
Gapping down: CYTR -64.3%, IMPV -9.7%, REN -3.6%, BLFS -3%, ALR -2.4%, REG -2.3%, AU -2.3%, FTNT -1.7%, RGLD -1.6%, CDE -1.4%, CHRS -1.3%, GOLD -1.3%, PANW -1.2%, NEM -0.8%, TSLA -0.7%
THOMSON REUTERS
EIKON
TM
- 12-Jul-2016 09:30:00 - BAD LOANS AT ITALIAN BANKS 199.99 BLN EUROS IN MAY FROM 198.35 BLN EUROS IN APRIL - BANK OF ITALY
- 12-Jul-2016 09:30:00 - ITALY BANK LENDING TO NON FINANCIAL COMPANIES UP 0.3 PERCENT IN MAY AFTER 0.6 PERCENT DROP IN APRIL - BANK OF ITALY
Gross bad loans at Italian banks 200 bln euros in May - BoI - Reuters News
12-Jul-2016 09:46:17
MILAN, July 12 (Reuters) - Italian banks in May held 200 billion euros ($222 billion) in loans to borrowers deemed insolvent, slightly up from the previous month, data showed on Monday, as lenders continue to suffer from the fallout of a deep three-year recession.
Bad debts have become the focus of concerns over Italian banks because they tie up precious capital and curb already weak profitability.
The Bank of Italy said in a monthly report that "sofferenze", the worst kind of bad loans, rose to 199.99 billion euros in gross terms in May from 198.35 billion euros in April. Net of writedowns, their value stood at 84.95 billion euros in May from 83.96 billion euros a month earlier.
(Reporting by Valentina Za, editing by Isla Binnie)
(( valentina.za@thomsonreuters.com ; +39 02 6612 9526; ))
Keywords: EUROZONE-BANKS/ITALY-BADLOANS (URGENT)
This e-mail is for the sole use of the intended recipient and contains information that may be privileged and/or confidential. If you are not an intended recipient, please notify the sender by return e-mail and delete this e-mail and any attachments. Certain required legal entity disclosures can be accessed on our website.